These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 39140716)

  • 1. Variation characteristics and clinical significance of
    Ma Q; Liu Y; Zhao H; Guo Y; Sun W; Hu R
    Hematology; 2024 Dec; 29(1):2387878. PubMed ID: 39140716
    [No Abstract]   [Full Text] [Related]  

  • 2. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
    J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
    Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
    Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.
    Tang G; DiNardo C; Zhang L; Ravandi F; Khoury JD; Huh YO; Muzzafar T; Medeiros LJ; Wang SA; Bueso-Ramos CE
    Hum Pathol; 2015 Jan; 46(1):65-73. PubMed ID: 25387813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
    Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
    Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
    Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
    Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are associated with complex karyotype, monosomal karyotype,
    Wang N; Yuan L; Jing Y; Fan K; Jin H; Lv C; Wang L; Yu L
    Leuk Lymphoma; 2021 Oct; 62(10):2466-2474. PubMed ID: 33904352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ball S; Loghavi S; Zeidan AM
    Leuk Lymphoma; 2023 Mar; 64(3):540-550. PubMed ID: 36323304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Poonsombudlert K; Mott S; Miller B; Dhakal P; Snow A; Hornberg S; Yodsuwan R; Strouse C; Shaikh H; Magalhaes-Silverman M; Sutamtewagul G
    Eur J Haematol; 2024 Jul; 113(1):16-23. PubMed ID: 38511425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia.
    Madarász K; Mótyán JA; Bedekovics J; Miltényi Z; Ujfalusi A; Méhes G; Mokánszki A
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eprenetapopt Plus Azacitidine in
    Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
    J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and characteristics of patients with
    Zhang L; Chen K; Li Y; Chen Q; Shi W; Ji T; Tao H; He Z; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2181773. PubMed ID: 36892252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
    Kojima K
    Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.